The awards celebrate researchers who have maximised the impact of their research
Professor Nick James accepting the STAMPEDE award on behalf of his team
The STAMPEDE trial has been awarded one of the first ever National Institute for Health and Care Research (NIHR) Impact Prizes.
The awards recognise major improvements in health over the last two decades, driven by research and scientific advances and have been awarded to researchers and teams who have had a major impact on the health and wealth of the nation, and globally. They celebrate researchers who have maximised the impact of their research by improving people’s lives or promoting economic growth.
STAMPEDE trial involved cooperation between The Royal Marsden and academic partner The Institute of Cancer Research, as well as University College London, Christie Hospital Manchester and University of Manchester and Oncology Institute of Southern Switzerland.
Improving outcomes for people with advanced prostate cancer
The findings from the trial have led to extended survival rates for men with advanced prostate cancer. They have changed global treatment guidelines and shed new light on long-term outcomes, including new indicators of treatment response, better targeting of therapies and interventions reducing complications.
This study received NIHR funding and support from NIHR Biomedical Research Centre at The Royal Marsden NHS Foundation Trust and NIHR Research Delivery Network. Read more about the study.
The first winners of the NIHR awards were announced at a ceremony in Birmingham by Professor Lucy Chappell, the Chief Scientific Advisor at the Department of Health and Social Care and Chief Executive Officer of the NIHR.
In total, NIHR received 136 entries. Of the 10 winners, five awards went to research teams and five to early-career researchers.
The STAMPEDE trial was awarded one of the five established investigator awards for research to assess different treatment options and improve outcomes for men with advanced prostate cancer.
STAMPEDE was deemed to be “a study with clear evidence of global impact"
Professor Nick James, Professor of Prostate and Bladder Cancer Research at The Royal Marsden and Group Leader on Prostate and Bladder Cancer Research at The Institute of Cancer Research, collected the award on behalf of the team. He said: “I'm very delighted to have won an award recognising the impact of the trial. The trial has been really huge, and to have just me here seems a bit unfair because it's a massive, massive team effort.
“Altogether, there's about 50 people working on the trial directly, at the moment, there's another 100 scientists of various sorts. Altogether, we’ve got 3000 people in the delegation logs for the trial, and 12,000 patients. So I’m privileged to be here to receive the award and to be representing a very large number of people.”
The judging panel described STAMPEDE as: “A study with clear evidence of global impact. It has impacted economic growth, saved lives and influenced policy, while also supporting the design of other studies.”
[Email](mailto:?subject=The Royal Marsden NHS Foundation Trust website&body=https%3A%2F%2Fwww.royalmarsden.nhs.uk)
Share